Compare SNGX & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | NCRA |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 13.2M |
| IPO Year | 1987 | N/A |
| Metric | SNGX | NCRA |
|---|---|---|
| Price | $1.69 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 304.6K | 49.7K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,106,275.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $0.70 |
| 52 Week High | $6.23 | $2.40 |
| Indicator | SNGX | NCRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 56.94 |
| Support Level | $1.55 | $0.83 |
| Resistance Level | $1.60 | $0.95 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 86.96 | 85.11 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.